Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies
Standard
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies. / Haen, Sebastian P; Eyb, Vicky; Mirza, Nora; Naumann, Aline; Peter, Andreas; Löffler, Markus W; Faul, Christoph; Vogel, Wichard; Bethge, Wolfgang A; Rammensee, Hans-Georg; Kanz, Lothar; Heni, Martin.
In: J CANCER RES CLIN, Vol. 143, No. 5, 05.2017, p. 759-771.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies
AU - Haen, Sebastian P
AU - Eyb, Vicky
AU - Mirza, Nora
AU - Naumann, Aline
AU - Peter, Andreas
AU - Löffler, Markus W
AU - Faul, Christoph
AU - Vogel, Wichard
AU - Bethge, Wolfgang A
AU - Rammensee, Hans-Georg
AU - Kanz, Lothar
AU - Heni, Martin
PY - 2017/5
Y1 - 2017/5
N2 - PURPOSE: Prolonged aplasia and graft failure (GF) represent life-threatening complications after hematopoietic cell transplantation (HCT) requiring suitable biomarkers for early detection and differentiation between GF and poor graft function (PGF). Uric acid (UA) is a strong immunological danger signal.METHODS: Laboratory results were analyzed from patients undergoing either allogeneic or autologous HCT or induction chemotherapy for acute leukemia (n = 50 per group, n = 150 total).RESULTS: During therapy, UA levels declined from normal values to hypouricemic values (all p < 0.001). Alongside hematopoietic recovery, UA serum levels returned to baseline values. During aplasia, UA levels remained low and started steadily increasing (defined as >two consecutive days, median one 2-day increase) at a median of 1 day before rising leukocytes in allogeneic HCT (p = 0.01) and together with leukocytes in autologous HCT (median one 2-day increase). During induction chemotherapy, a UA increase was also observed alongside rising leukocytes/neutrophils but also several times during aplasia (median 3 increases). Most HCT patients had no detectable leukocytes during aplasia, while some leukocytes remained detectable after induction therapy. No increase in UA levels was observed without concomitant or subsequent rise of leukocytes.CONCLUSIONS: Changes in UA serum levels can indicate incipient or remaining immunological activity after HCT or induction therapy. They may, therefore, help to differentiate between PGF and GF.
AB - PURPOSE: Prolonged aplasia and graft failure (GF) represent life-threatening complications after hematopoietic cell transplantation (HCT) requiring suitable biomarkers for early detection and differentiation between GF and poor graft function (PGF). Uric acid (UA) is a strong immunological danger signal.METHODS: Laboratory results were analyzed from patients undergoing either allogeneic or autologous HCT or induction chemotherapy for acute leukemia (n = 50 per group, n = 150 total).RESULTS: During therapy, UA levels declined from normal values to hypouricemic values (all p < 0.001). Alongside hematopoietic recovery, UA serum levels returned to baseline values. During aplasia, UA levels remained low and started steadily increasing (defined as >two consecutive days, median one 2-day increase) at a median of 1 day before rising leukocytes in allogeneic HCT (p = 0.01) and together with leukocytes in autologous HCT (median one 2-day increase). During induction chemotherapy, a UA increase was also observed alongside rising leukocytes/neutrophils but also several times during aplasia (median 3 increases). Most HCT patients had no detectable leukocytes during aplasia, while some leukocytes remained detectable after induction therapy. No increase in UA levels was observed without concomitant or subsequent rise of leukocytes.CONCLUSIONS: Changes in UA serum levels can indicate incipient or remaining immunological activity after HCT or induction therapy. They may, therefore, help to differentiate between PGF and GF.
KW - Adult
KW - Aged
KW - Anemia/blood
KW - Biomarkers, Tumor/blood
KW - Blood Cell Count
KW - Bone Marrow/immunology
KW - Female
KW - Graft Survival/immunology
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Humans
KW - Leukemia, Myeloid, Acute/blood
KW - Male
KW - Middle Aged
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
KW - Uric Acid/blood
KW - Young Adult
U2 - 10.1007/s00432-017-2348-z
DO - 10.1007/s00432-017-2348-z
M3 - SCORING: Journal article
C2 - 28210842
VL - 143
SP - 759
EP - 771
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 5
ER -
